COPD, Mechanical Ventilation, Weaning From Mechanical Ventilation
Conditions
Keywords
COPD, Doxapram, Diaphragmatic excursion
Brief summary
Researchers aim to evaluate the impact of doxapram administration on diaphragmatic excursion in chronic obstructive pulmonary disease (COPD) patients undergoing spontaneous breathing trial
Detailed description
doxapram will be administered intravenously (IV) during spontaneous breathing trial. diaphragmatic excursion will be evaluated by an expert in respiratory muscle ultrasound
Interventions
DRUGDoxapram
Doxapram will be given as 1.5 mg/kg will be given 10 minutes after the initiation of SBT
Sponsors
Cairo University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Patients with moderate to severe chronic obstructive pulmonary disease undergoing spontaneous breathing trial
Exclusion criteria
* Refusal Allergy to doxapram neuromuscular disorders inability to evaluate the diaphragm
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| • Diaphragmatic excursion in mm | before and 10 minutes after doxappram |
Secondary
| Measure | Time frame |
|---|---|
| Arterial blood gases | before and 10 minutes after doxapram |
| Respiratory rate | before and 10 minutes after doxapram |
Countries
Egypt
Contacts
Primary ContactMina Helmy, MD
Outcome results
None listed